Generalized Anxiety Disorder

Psychedelic-Assisted Therapy Advancements Create A New Horizon For Mental Health In Colorado
MindMed Receives FDA 'Breakthrough Therapy' Designation For LSD As Anxiety Treatment, Shares Positive Results About Related Clinical Trials
Psilocybin-Assisted Therapy Achieves Positive Clinical Trial Results For Treating Generalized Anxiety
MindMed Receives FDA 'Breakthrough Therapy' Designation For LSD As Anxiety Treatment, Shares Positive Results About Related Clinical Trials
Psilocybin-Assisted Therapy Achieves Positive Clinical Trial Results For Treating Generalized Anxiety
MindMed's 2024 Plans: Anxiety Treatment Stands, LSD Microdosing For ADHD Will Be Discontinued
Groundbreaking Study: LSD Tartrate Reduces Anxiety Effectively, Says MindMed

Generalized Anxiety Disorder Recent News

Trial On DMT Drug For Anxiety And Depression Ends Participant Dosing, Study Results Soon Released
Clinical-stage biopharma company Cybin Inc. (NYSE: CYBN) has completed participant dosing on the part 2 of 3 of its Phase 1 trial assessing intravenous (IV) administration of proprietary DMT drug CYB004.
Psychedelic Trials Update: Treating Meth Addiction, Fibromyalgia & General Anxiety Disorder
Three companies have provided updates on their efforts to assess different psychedelics for treating a widely varied set of conditions.
Two New Studies On Classical Psychedelics: Grading Ketamine's Components, Tuning Down Psilocybin Dosing
Awakn’s First Study On Novel S-Ketamine Formulation To Assess Dissociative Effect
Australian Psychedelics: Phase 2 Trial On Psilocybin For Anxiety Will Soon Share Results
Australian biopharma company developing therapeutic cannabinoid products and psychedelic medicines Incannex Healthcare (NASDAQ:
Psychedelics Companies Join The Race To Develop Much-Needed Anxiety Treatment
Life sciences biotech company Cybin Inc. (NYSE: CYBN) announced its selection of the Generalized Anxiety Disorder (GAD) with or without Major Depressive Disorder (MDD) as the target indication for its proprietary deuterated DMT molecule, CYB004.
Where Are Psychedelics Headed In 2023? These Two Heavy Hitters Share Their Plans
It’s the beginning of 2023 and psychedelics companies are updating the public on their developmental and clinical progress as well as their selected milestones for the year.
These Are The 11 Biggest Psychedelics News And Trends You May Have Missed Last Year
What a year for psychedelics!
MindMed's First Patient Dosing Clinical Trial With LSD For Treatment Of Generalized Anxiety Disorder
The clinical-stage biopharma company Mind Medicine -also known as MindMed (NASDAQ: MNMD), which recently made headlines reg